Vir Biotechnology, Inc. $VIR Shares Bought by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. raised its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 43.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 742,674 shares of the company’s stock after acquiring an additional 225,544 shares during the quarter. Goldman Sachs Group Inc. owned 0.54% of Vir Biotechnology worth $4,813,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its position in Vir Biotechnology by 26.2% in the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock valued at $68,000 after acquiring an additional 2,171 shares in the last quarter. Focus Partners Wealth grew its position in Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after acquiring an additional 2,566 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Vir Biotechnology by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,290 shares of the company’s stock valued at $248,000 after acquiring an additional 3,209 shares in the last quarter. Captrust Financial Advisors grew its position in Vir Biotechnology by 29.6% in the fourth quarter. Captrust Financial Advisors now owns 20,503 shares of the company’s stock valued at $150,000 after acquiring an additional 4,683 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Vir Biotechnology by 524.3% in the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after acquiring an additional 5,972 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $4.99, for a total transaction of $109,780.00. Following the sale, the director directly owned 1,254,391 shares in the company, valued at $6,259,411.09. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $5.47, for a total transaction of $37,174.12. Following the sale, the executive vice president owned 108,204 shares in the company, valued at approximately $591,875.88. This represents a 5.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 76,382 shares of company stock worth $388,550. Company insiders own 16.00% of the company’s stock.

Vir Biotechnology Stock Performance

VIR stock opened at $4.86 on Wednesday. The stock has a market capitalization of $675.15 million, a price-to-earnings ratio of -1.22 and a beta of 1.28. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $14.45. The stock’s fifty day moving average is $5.06 and its two-hundred day moving average is $5.52.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business’s quarterly revenue was down 60.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.02) earnings per share. As a group, analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on VIR shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research report on Monday. Raymond James Financial started coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They issued an “outperform” rating for the company. Evercore ISI initiated coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective for the company. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their price target for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, Needham & Company LLC reissued a “buy” rating and set a $14.00 price target on shares of Vir Biotechnology in a research report on Thursday, May 22nd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).